Table 1.

Baseline characteristics of L-carnitine and placebo cohorts at randomization (excludes the 3 study subjects that either were lost to follow-up or not compliant with the study protocol)^*.

	L-carnitine (n=16)	Placebo (n=11)
Age (y)	6.3±2.4**	6.7±1.6
Gender (n)
Male	14	9
Female	2	2
Race (n)
Caucasian	12	9
Minorities***	4	2
Bodyweight (Kg)	22.3±5.6	23.5±3.7
Autism Spectrum Disorder (n)
Autism	10	8
PDD-NOS/Asperger’s Disorder	6	3

^*Kg – Kilogram; PDD-NOS – Pervasive Developmental Disorder – Not Otherwise Specified. Age, Gender, Race, Bodyweight, or autism spectrum disorder status did not significantly differ between the 2 treatment groups.

^**mean ±SD;

^***includes: Blacks, Asians, and Hispanics.